PaxVax has announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol®
Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, has entered into a global collaboration with Pfizer for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus vectors for the potential treatment of hemophilia B.
Just a few years ago, early adopters of e-cigarettes got their fix by clumsily screwing together a small battery and a plastic cartridge containing cotton soaked with nicotine. Now, the battery-powered contraptions have computer chips to regulate puffs and temperature, track usage, talk to other electronic devices and even blink when "vapers" are near each other.
Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.
In its annual Top Health Industry Issues of 2015 report, PwC’s Health Research Institute (HRI) anticipates that the $2.8 trillion U.S. healthcare sector will start feeling like a true market. HRI’s report explores the top 10 trends that are expected to shape the sector in 2015
Meda, a Recipharm’s customer, announced that they will transfer supply of their mainly Swedish penicillin products and manufacture offshore with other suppliers. The manufacturing contract with Recipharm Strängnäs will therefore be terminated as of December 31, 2015.
Kindred Biosciences, a biopharmaceutical company focused on saving and improving the lives of pets, has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
Many HealthCare.gov customers will face higher costs next year, the Obama administration acknowledged in a report that shows average premiums rising modestly. However, officials said millions of consumers who are currently enrolled can mitigate the financial consequences if they are willing to shop around for another plan in a marketplace that's becoming more competitive.
The Parkinson’s Disease (PD) treatment pipeline is characterized by a high degree of innovation and diverse molecular targets, with 37% of 302 products holding first-in-class status, says business intelligence provider GBI Research.
Incyte Corporation announced that the FDA has approved Jakafi® for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi, an oral medication, is the first and only product approved by the FDA for PV, a rare and progressive blood cancer.
Nearly two decades ago, researcher James Allison found a way to use the body’s own immune system to kill malignant cells, a discovery that’s transforming cancer treatment and saving lives.
Health officials are telling doctors that the flu vaccine may not be very effective this winter. As flu season begins to ramp up, officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year.
Mylan has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.
The facility recently completed the integration of staff into the state-of-the-art manufacturing suite and product development laboratories. The U.S. Operations Center will house 275 employees across management, administration, commercial operations, manufacturing and R&D, a set up designed to allow unique opportunities for collaboration across various operational disciplines.
Catalent Pharma Solutions has reached an exclusive development and licensing agreement with Swiss-based development-stage biopharmaceutical company SELLAS Life Sciences Group, to support the development and therapeutic reprofiling of zolpidem using Catalent’s OSDrC® OptiDose™ drug delivery technology.